GAS-CHROMATOGRAPHY MASS-SPECTROMETRY ASSAYS FOR THE DETERMINATION OF DEBRISOQUINE AND SPARTEINE METABOLITES IN MICROSOMAL FRACTIONS OF RAT-LIVER

被引:3
作者
HO, JW
MOODY, DE
机构
[1] Center for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah College of Pharmacy, Salt Lake City
关键词
D O I
10.1016/0003-2697(92)90323-Y
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Debrisoquine and sparteine are prototype substrates of a genetic deficiency in cytochrome P450-dependent drug metabolism. Sensitive assays of in vitro oxidation of sparteine and debrisoquine are required for evaluation of this polymorphism. The activities were measured by quantitative analysis of 2-dehydrosparteine and 4-hydroxydebrisoquine production, respectively, using capillary column gas chromatography coupled with mass selective ion detection. With a single extraction, separation of parent drug, metabolite, and a suitable internal standard was readily achievable. Time-dependent production of both metabolites could be detected from as little as 40 μg of microsomal protein. Both activities showed a maximal activity with a 240-min incubation period. The ability to simultaneously quantify the parent drug and its metabolite suggests it would also be useful for evaluation of in vivo metabolism. © 1992.
引用
收藏
页码:348 / 351
页数:4
相关论文
共 18 条
[1]   ANIMAL MODELING OF HUMAN POLYMORPHIC DRUG OXIDATION - THE METABOLISM OF DEBRISOQUINE AND PHENACETIN IN RAT INBRED STRAINS [J].
ALDABBAGH, SG ;
IDLE, JR ;
SMITH, RL .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1981, 33 (03) :161-164
[2]   CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547
[3]   REGIOSELECTIVITY AND STEREOSELECTIVITY OF THE METABOLISM OF THE CHIRAL QUINOLIZIDINE ALKALOIDS SPARTEINE AND PACHYCARPINE IN THE RAT [J].
EBNER, T ;
MEESE, CO ;
EICHELBAUM, M .
XENOBIOTICA, 1991, 21 (07) :847-857
[4]   POLYMORPHIC OXIDATION OF SPARTEINE AND DEBRISOQUINE - RELATED PHARMACOGENETIC ENTITIES [J].
EICHELBAUM, M ;
BERTILSSON, L ;
SAWE, J ;
ZEKORN, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (02) :184-186
[5]  
GUENGERICH FP, 1989, ANNU REV PHARMACOL, V29, P241
[6]   METABOLISM OF [C-14]-DEBRISOQUINE IN MAN [J].
IDLE, JR ;
MAHGOUB, A ;
ANGELO, MM ;
DRING, LG ;
LANCASTER, R ;
SMITH, RL .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 7 (03) :257-266
[7]  
KAHN GC, 1985, DRUG METAB DISPOS, V13, P510
[8]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAYS FOR BUFURALOL 1'-HYDROXYLASE, DEBRISOQUINE 4-HYDROXYLASE, AND DEXTROMETHORPHAN O-DEMETHYLASE IN MICROSOMES AND PURIFIED CYTOCHROME-P-450 ISOZYMES OF HUMAN-LIVER [J].
KRONBACH, T ;
MATHYS, D ;
GUT, J ;
CATIN, T ;
MEYER, UA .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :24-32
[9]   PURIFICATION AND CHARACTERIZATION OF THE RAT-LIVER MICROSOMAL CYTOCHROME-P-450 INVOLVED IN THE 4-HYDROXYLATION OF DEBRISOQUINE, A PROTOTYPE FOR GENETIC-VARIATION IN OXIDATIVE DRUG-METABOLISM [J].
LARREY, D ;
DISTLERATH, LM ;
DANNAN, GA ;
WILKINSON, GR ;
GUENGERICH, FP .
BIOCHEMISTRY, 1984, 23 (12) :2787-2795
[10]   DETERMINATION OF DEBRISOQUINE AND ITS 4-HYDROXY METABOLITE IN BIOLOGICAL-FLUIDS BY GAS-CHROMATOGRAPHY WITH FLAME-IONIZATION AND NITROGEN-SELECTIVE DETECTION [J].
LENNARD, MS ;
SILAS, JH ;
SMITH, AJ ;
TUCKER, GT .
JOURNAL OF CHROMATOGRAPHY, 1977, 133 (01) :161-166